CLNN logo

CLNN Clene Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$3.50
+0.08 (+2.34%)

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submi…

Market Cap: $50.40Mclene.com

Price

No data yet.

Social Signal Score

40
5d
—
30d
50
2 mentions
—
60d
33
4 mentions
—
90d
37
7 mentions
—
news: 7

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 1Sell 0Strong Sell 0
Avg price target$50+1328.6%
Low $50Median $50High $50
Current Consensus

Revenue

$56.0K
$0.00$89.7K$179.3K$269.0K
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-2.35
$-2.55–$-2.15
2 analysts
FY2026
$-2.01
$-2.03–$-1.98
2 analysts
FY2027
$-1.75
$-2.12–$-1.36
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert Etherington
Sector
Healthcare
Industry
Biotechnology
Employees
78
Beta
0.92
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-24.02
clene.com